Exelixis to acquire Artemis

EXEL will acquire Artemis Pharmaceuticals (Cologne, Germany) for 2.1 million shares, valuing the deal at $24.3 million based on EXEL's Monday close at $11.55. The acquisition combines EXEL's comparati...